Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

Buy-and-Bill

COVID-19

Case-Based Roundtable

Chronic Hand Eczema

Chronic Spontaneous Urticaria 

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Prurigo Nodularis

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

Clinical Case Collective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Perspectives in Dermatology

Polls

Spot Test

Editorial Advisory Board

Partners

Subscribe

and joined the MJH Life Sciences team in February 2023. She attended Kent State University and earned a Bachelor of Science degree in journalism with minors in public relations and creative writing. She enjoys making and listening to music, reading, and spending time with her cats, Astrid and Marceline.

Articles

Paller discusses the promising phase 3 trial SELVA trial results for Qtorin 3.9% rapamycin gel, an investigative treatment for microcystic lymphatic malformations.

Amy Paller, MD, MS, Discusses Phase 3 Trial Results for Qtorin 3.9% Rapamycin Gel

Raj Chovatiya, MD, PhD, MSCI, is a clinical associate professor at Rosalind Franklin University Chicago Medical School, founder and director of the Center for Medical Dermatology and Immunology Research in Chicago, and 

Raj Chovatiya, MD, PhD, MSCI, provides insights on the clinical advantages of JAK inhibitors for atopic dermatitis.

JAK Inhibitors as Flexible, Fast-Acting Option for Refractory AD

Omar Noor, MD, FAAD, explores the complex immune and cellular mechanisms behind CHE and highlights its significant physical and emotional toll on patients.

Understanding Chronic Hand Eczema: Cellular Mechanisms and Therapeutic Implications

Maddi Hebebrand is an associate editor of 

and joined the MJH Life Sciences team in May 2024. She attended Baldwin Wallace University, studying Media Production and Film, and received her Masters in Digital Media from Ohio University. When she's not writing, Maddi loves to read, attend concerts and spend time with her family. 

Complete remission was achieved in over 87% of dupilumab users and 64% of omalizumab users.

New Insights into Biologic Therapies for BP

About

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times and Multimedia Medical, LLC

Facebook

Linkedin

Topics

Acne

Pigmentary Disorders

Practice Management

Psoriasis

Psoriatic Arthritis

Rosacea

Conference

1rem

Conference Archive

Perspectives: The Evolution of Aesthetics

Victor Ross, MD, board-certified dermatologist and dermatologic surgeon in San Diego, California, spoke about different technologies available for microneedling and energy-based devices. 

Deep Dive into Microneedling with Energy-Based Devices

Opening the symposium in a circle of sparks and salsa dancing, Shino Bay Aguilera, DO, talks the importance of diversity and wellness in aesthetics. 

 Shino Bay Aguilera, DO, Opens ABM Perspectives with a Bang